Background illustration for clinical trials search

Paid Clinical Trials Denver

Discover 1,550 paid clinical trials in Denver, Colorado. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

for
Head and Neck Squamous Cell Carcinoma HNSCC,
Location: Denver CO, Austin TX, San Antonio TX, San Diego CA,
Sponsor: Sutro Biopharma, Inc.

Sex: All

Age: 18+

Code: NCT07227168

Phase1, Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

for
Acute Myeloid Leukemia (AML)
Location: Denver CO, Aurora CO, Albuquerque NM, Gilbert AZ,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT07007312

Phase3, Recruiting

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

for
Myeloproliferative Neoplasms
Location: Denver CO, Salt Lake City UT, Phoenix AZ, Dallas TX,
Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT07008118

Phase1, Recruiting

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

for
Solid Tumor Malignancies
Location: Denver CO, Salt Lake City UT, Irving TX, Austin TX,
Sponsor: Kumquat Biosciences Inc.

Sex: All

Age: 18+

Code: NCT07207707

Phase1, Recruiting

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

for
AML, MDS
Location: Denver CO, Aurora CO, Dallas TX, Austin TX, Duarte CA,
Sponsor: TScan Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07702578

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

for
Advanced Cancer, Advanced Solid Tumors
Location: Denver CO, Nashville TN, New Orleans LA, Orlando FL
Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.

Sex: All

Age: 18 - 70+

Code: NCT06656390

Phase1, Phase2, Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

for
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Location: Denver CO, Dallas TX, Iowa City IA, Madison WI,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 19+

Code: NCT06974786

Phase2, Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

for
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Location: Denver CO, St Louis MO, San Antonio TX, Duarte CA,
Sponsor: Allotera Therapeutics

Sex: All

Age: 0+

Code: NCT06514794

Phase2, Recruiting

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

for
Waldenstrom Macroglobulinemia
Location: Denver CO, Dallas TX, Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT06561347

Phase2, Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

for
Hematologic Malignancies, Inherited Disorders of Metabolism,
Location: Denver CO, Aurora CO, Salt Lake City UT, Omaha NE,
Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All

Age: 0+

Code: NCT01351545

Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for
Myelofibrosis
Location: Denver CO, Salt Lake City UT, Tucson AZ, Minneapolis MN,
Sponsor: Sumitomo Pharma America, Inc.

Sex: All

Age: 18+

Code: NCT04176198

Phase1, Phase2, Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

for
Multiple Myeloma
Location: Denver CO, Aurora CO, Phoenix AZ, San Diego CA,
Sponsor: European Myeloma Network B.V.

Sex: All

Age: 18+

Code: NCT05243797

Phase3, Recruiting

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

for
Graft Versus Host Disease
Location: Denver CO
Sponsor: Colorado Blood Cancer Institute

Sex: All

Age: 18 - 70+

Code: NCT02178683

Phase3, Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

for
Multiple Myeloma
Location: Denver CO, Orange CA, Los Angeles CA, Houston TX,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT05828511

Phase1, Phase2, Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

for
High-risk Smoldering Multiple Myeloma,
Location: Denver CO, Portland OR, Boston MA
Sponsor: Irene Ghobrial, MD

Sex: All

Age: 18+

Code: NCT05469893

Phase2, Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

for
Hematologic Malignancies, Waldenstroms Macroglobulinaemia,
Location: Denver CO, Springdale AR, Dallas TX, Spokane WA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04728893

Phase2, Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Relapsed and/or Refractory Multiple Myeloma
Location: Denver CO, Duarte CA, Stanford CA, San Francisco CA,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06153251

Phase1, Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

for
B-cell Acute Lymphoblastic Leukemia
Location: Denver CO, Aurora CO, Austin TX, San Antonio TX,
Sponsor: Cellectis S.A.

Sex: All

Age: 15 - 50

Code: NCT04150497

Phase1, Phase2, Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar,
Location: Denver CO, Omaha NE, Oklahoma City OK, Kansas City KS,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06001788

Phase1, Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

for
Metastatic Uveal Melanoma, Cutaneous Melanoma,
Location: Denver CO, Los Angeles CA, Houston TX, Nashville TN,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT03947385

Phase1, Phase2, Recruiting

Denver is a pivotal hub for clinical trials, thanks to its sturdy healthcare network and renowned medical research institutions. Prominent centers such as the University of Colorado Anschutz Medical Campus, Denver Health, and Children’s Hospital Colorado are at the forefront of groundbreaking studies focusing on areas including cancer research, neurological disorders, and chronic diseases.

Denver's strong emphasis on collaboration among healthcare providers, researchers, and community organizations fosters an environment conducive to medical advancements. By participating in clinical trials in Denver, individuals not only gain access to cutting-edge therapies but also contribute significantly to the progress of medical science.

Why choose Denver for clinical trials?

Denver boasts a diverse population which helps increase the reliability and relevance of research outcomes. The city is also home to top-tier medical research facilities known for innovative approaches to healthcare and a strong emphasis on medical breakthroughs.

Choosing to participate in a clinical trial in Denver means contributing to vital medical research while benefiting from a well-coordinated and supportive clinical research infrastructure. This environment not only promotes advancements in medical science but also provides participants with access to pioneering therapies and specialized care throughout the study.

Common conditions studied in Denver

Local regulations and guidelines

Benefits of participating in clinical trials

How to enroll in a clinical trial in Denver